Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine filings document the regulatory and financial record of a clinical-stage biopharmaceutical company developing hematologic disease therapies. Its Form 8-K disclosures cover quarterly and annual financial results, corporate updates, clinical-program materials for bitopertin, DISC-0974 and DISC-3405, and FDA communications related to the bitopertin New Drug Application for erythropoietic protoporphyria.
The filing record also includes proxy materials covering board matters, executive compensation and shareholder voting items. Material-event reports describe Regulation FD presentations, operating runway disclosures, restructuring actions following regulatory developments, and risk-related statements around clinical trials, regulatory pathways, research spending and capital resources.
Disc Medicine Chief Operating Officer Jonathan Yu reported a small, pre-planned insider transaction in Disc Medicine, Inc. common stock. On June 26, 2026, he exercised stock options to acquire 300 shares of common stock at $13.50 per share, then sold 300 shares of common stock at an average price of $72.50 per share in an open-market transaction.
The filing notes these trades were executed under a previously adopted Rule 10b5-1 trading plan, indicating they were scheduled in advance rather than timed discretionarily. A related footnote explains that the option grant vests in 48 equal monthly installments starting from December 29, 2022, contingent on Yu’s continued service.
Disc Medicine amended its existing Loan and Security Agreement with Hercules Capital to extend access to debt financing and adjust covenant timing. On June 25, 2026, the company agreed to immediately draw $30,000,000 from the Tranche 1-B Advance.
The prior $50,000,000 Tranche 1-C was restructured into a $25,000,000 loan available at the company’s option through March 31, 2027 and a separate $25,000,000 Tranche 1-D available through April 30, 2027. Draw periods for Tranche 2 and Tranche 3 were also extended to December 15, 2027 and June 30, 2028, respectively, and the parties set an initial testing date of July 1, 2028 for the amended minimum cash covenant.
Form 144 notice for IRON: proposed sale of 2,500 common shares via option exercise. The filing lists an intended disposition of 2,500 shares on 06/26/2026 described as an Exercise of Stock Options with $175,400.00 shown in the row. The filing also records prior 10b5-1 sales by Rahul Khara of 7,500 shares on 06/18/2026 for $526,660.50. Broker information shown: Morgan Stanley Smith Barney LLC, New York.
Disc Medicine, Inc. Chief Operating Officer Jonathan Yu Yen-Wen executed an options-related trade involving company stock. He exercised stock options to acquire 9,700 shares of common stock at $13.50 per share, then sold 9,700 shares in an open-market transaction at a weighted average price of $72.6593 per share.
The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 17, 2026. Following these trades, he directly holds 54,324 shares of common stock and 24,147 stock options that are scheduled to vest monthly through December 29, 2026 and expire on December 28, 2032.
Disc Medicine, Inc. held its 2026 annual meeting of stockholders on June 18, 2026. Stockholders elected three Class III directors — Donald Nicholson, Ph.D., John Quisel, J.D., Ph.D., and William White, M.P.P., J.D. — each for a three-year term ending at the 2029 annual meeting.
Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, indicating overall support for current pay practices. In addition, they ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Disc Medicine Chief Legal Officer Rahul Khara reported an exercise-and-sell transaction in company common stock. On June 18, 2026, he exercised stock options to acquire 7,500 shares at an exercise price of $14.69 per share, then sold 7,500 shares in open-market trades at weighted average prices between about $69.35 and $71.81. The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan. Following the transactions, he directly holds 52,173 shares of Disc Medicine common stock.
Disc Medicine, Inc.’s CEO John D. Quisel reported mixed insider activity in Common Stock. On June 18, 2026, he sold a total of 34,000 shares in open-market transactions at weighted average prices within ranges from $69.35 to $71.85 per share under a pre-arranged Rule 10b5-1 trading plan. On the same date, he exercised a stock option to acquire 34,000 shares of Common Stock at an exercise price of $9.86 per share. After these transactions, he directly holds 226,064 shares of Common Stock and 41,375 stock options remain outstanding, indicating a sizable continuing equity stake.
Disc Medicine director William Richard White received a grant of stock options for 6,212 shares of common stock. The options have an exercise price of $70.79 per share and expire on June 17, 2036. They vest at the earlier of the company’s 2027 annual stockholder meeting or one year from the grant date, subject to his continued service.
Disc Medicine, Inc. director Liam Ratcliffe received a grant of stock options covering 6,212 shares of common stock. The options have an exercise price of $70.79 per share and expire on June 17, 2036.
These options vest on the earlier of the company’s 2027 annual stockholder meeting or the one-year anniversary of the grant date, as long as he continues to serve through that vesting date. Following this grant, he holds 6,212 stock options directly, reflecting a compensation-related award rather than an open-market trade.
Disc Medicine, Inc. director Donald William Nicholson received a grant of stock options, giving him the right to buy 6,212 shares of common stock at an exercise price of $70.79 per share. These options expire on June 17, 2036 and vest upon the earlier of the company’s 2027 annual stockholder meeting or the one-year anniversary of the grant date, as long as he continues serving through that vesting date. Following this grant, he holds stock options covering 6,212 shares directly.